NCT04590781 - Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

March 24, 2022

Study Completion Date

March 24, 2022

Conditions

Merkel Cell CarcinomaSmall Cell Lung Cancer

Interventions

BIOLOGICAL

XmAb18087

Monoclonal bispecific antibody

DRUG

XmAb18087 ± Pembrolizumab

Trial Locations (7)

Memorial Sloan Kettering, New York

OU Health, Stephenson Cancer Center, Oklahoma City

USC/Norris Comprehensive Cancer Center, Los Angeles

City of Hope, Duarte

Swedish Cancer Institute, Seattle

University of Washington, Seattle

Dartmouth Hitchcock Medical Center, Lebanon